# Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

> **NCT03578029** · PHASE2 · TERMINATED · sponsor: **Lenus Therapeutics, LLC** · enrollment: 4 (actual)

## Conditions studied

- Junctional Epidermolysis Bullosa
- Dystrophic Epidermolysis Bullosa

## Interventions

- **DRUG:** RGN-137
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03578029
- **Lead sponsor:** Lenus Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-22
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-11-23
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03578029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03578029, "Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03578029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*